Compare ADCT & NATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADCT | NATR |
|---|---|---|
| Founded | 2011 | 1972 |
| Country | Switzerland | United States |
| Employees | N/A | 806 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.2M | 392.7M |
| IPO Year | 2019 | 1995 |
| Metric | ADCT | NATR |
|---|---|---|
| Price | $3.13 | $21.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $7.75 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.1M | 71.3K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.86 | ★ 165.00 |
| EPS | N/A | ★ 0.29 |
| Revenue | $81,357,000.00 | ★ $480,144,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | $66.49 | $4.82 |
| P/E Ratio | ★ N/A | $76.79 |
| Revenue Growth | ★ 14.85 | 5.67 |
| 52 Week Low | $1.83 | $12.97 |
| 52 Week High | $4.98 | $28.14 |
| Indicator | ADCT | NATR |
|---|---|---|
| Relative Strength Index (RSI) | 27.42 | 24.82 |
| Support Level | $3.11 | $21.27 |
| Resistance Level | $4.73 | $27.74 |
| Average True Range (ATR) | 0.22 | 1.27 |
| MACD | -0.06 | -0.43 |
| Stochastic Oscillator | 3.40 | 9.25 |
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.